Siltuximab, a monoclonal antibody against IL-6, is in clinical trials for therapies including; combinatorial treatment of metastatic renal cell carcinoma, multiple myeloma, and prostate cancer [83–86]. This evidence concerns the gene IL6 and Familial prostate cancer.